Pharma Faces / Shirley Xu, Baxter China
The pharma industry tends to see a lot of personnel movement, particularly at management levels, but since the Chinese market started heating up a few years ago, the labour market…
Address: Building 4, 998 Halei Road, Shanghai ,China
Tel: +86 21 5079 5188
Web: http://www.criver.com/en-US/Pages/home.aspx
For more than 60 years, Charles River has been helping our global partners accelerate drug discovery and development by providing them with high-quality research models and preclinical and clinical support services. Our offerings span the entire drug development process, from discovery through market approval, providing our clients a seamless partnership throughout.
From the global standardization of our research models, to the high standards we set for our professional team and our state-of-the-art facilities and technologies, we can customize our products and services to meet customer’s specific research needs. With facilities around the world, Charles River is the ideal partner for moving a compound through development in a rational, cost-effective and timely manner.
Research models and preclinical and clinical support services.
The pharma industry tends to see a lot of personnel movement, particularly at management levels, but since the Chinese market started heating up a few years ago, the labour market…
Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually…
Rae Yuan, president of Sinovant Sciences, shares the company’s “transformer” strategy culminating in a strong pipeline of innovative products spanning eight therapeutic areas, and their mission to serve the needs…
Hans Schmid, chairman; and Enrico Magnani, GM, of global cancer supportive care leader Helsinn Pharmaceuticals’ operations in China, share the Swiss company’s strategy in China, having entered in 2012; the…
The rate of diabetes in China has exploded: the number of diabetic patients has surpassed 100 million and is expected to increase to 150 million by 2040. Dr Qinghua Wang,…
Dr Dong Wei, CEO of EdiGene, shares the fascinating story behind the establishment of EdiGene, including his close relationship with EdiGene founder Professor Wensheng Wei; the insights he bring from…
Speaking in May 2019, Dr Dajun Yang, chairman, executive director and CEO of Ascentage Pharma, shares the company’s top highlights over the past decade; their strong product pipeline and portfolio…
Mark Lotter, founder and CEO of Nuance Biotech, explains why he decided to return to the China market to establish Nuance Biotech, two years after his retirement. He also shares…
Michael Zhang, chairman of Peijia Medical, shares Peijia Medical’s mission to become a two-platform medical device company as well as the partner of choice for physicians in China and globally.…
PharmaBoardroom recently analysed the contents of 10 interviews conducted with country managers at multinational pharma companies in China. We found some underlying themes present in the majority of the interviews,…
Dr. Zhang Yu, CEO of Aeon Therapeutics, shares the unique journey that motivated him to establish Aeon Therapeutics, as a joint venture of Chinese VcanBio and US-based Eureka Therapeutics, to…
With proactive government support and an increasingly specialised workforce, China has become one of the leading nations in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, along with the…
See our Cookie Privacy Policy Here
